efficacy of semaglutide and safety once-weekly 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial Comparing Semaglutide, Liraglutide, and Tirzepatide:

#DiabetesCare #PrecisionMedicine #MetabolicHealth #LowerTheDose #HealthcareInnovation To view or add a comment, sign in In our recent publication in Diabetes, Obesity and Metabolism, together with Professors Kokkinos and le Roux, we articulate a perspective grounded in robust scientific evidence, yet one that is rarely expressed with candor in the public scientific discourse: that, as with any other chronic disease, pharmacotherapy should constitute the central pillar in the treatment of obesity, while other approaches retain an important but complementary role

For instance, clinical trials state that retatrutide reduces liver fat, which is a type of stubborn fat associated with increased health risks

The errors are leading some patients to take up to 20 times the amount of intended semaglutide, the FDA reports

Svart MV, Voss TS, Bayat M, et al

I worry that in dealing with people with cravings, and people at risk of overdosing and other problems, that we need to understand and appreciate the uncertainties here more. He says that another issue that must be explored further before prescribing GLP-1s to prevent or treat addictions is the ability of the brain to adapt

Treating insulin resistance, hypertension, and dyslipidemia improves overall well-being and may indirectly enhance reproductive capacity